Effect of omega-3 fatty acid supplementation in patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.

Phase 2

• Conditions: Condition 1: type 2 diabetes. Condition 2: Nonalcoholic fatty liver disease (NAFLD).; Non-insulin-dependent diabetes mellitus; Fatty (change of) liver, not elsewhere classified (NAFLD)

• Registration Number: IRCT2016102530489N1
• Lead Sponsor: Yazd Shahid Sadoughi University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Inclusion criteria include type II diabetes, nonalcoholic fatty liver disease, non-participation in the intervention program, ranging in age from 18 to 60 years, both men and women, not using insulin therapy, without any kidney; liver heart; thyroid, bleeding disorders or malignancies and lack of special diet
Exclusion criteria from the study: type1 diabetes,alcoholic fatty liver disease, hepatitis type B and C, abuse alcohol, consume drugs and blood thinners such as warfarin, heparin or pentoxifylline, who recently had surgery, having allergic to seafood, uncontrolled high blood pressure, a weakened immune system and use drugs that cause fatty liver, such as steroids, estrogen, amiodarone, tamoxifen in the last 6 months

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified